| Catalog No. | Size | Price (USD) |
| 11007-MM06-50 | 50 µL | $147.96 |
| 11007-MM06-100 | 100 µL | $251.64 |
| 11007-MM06-200 | 200 µL | $355.32 |
General Information
| Product name | Anti-CD20 Antibody, Mouse Monoclonal |
| Validated applications | IHC-P (FAQ Protocol) |
| Species reactivity | Reacts with: Human, Cynomolgus |
| Specificity | Human, Cynomolgus |
| Immunogen | Recombinant Human CD20/MS4A1 Protein (Catalog#11007-H07H2) |
| Preparation | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human CD20/MS4A1 (rh CD20/MS4A1; Catalog#11007-H07H2; NP_068769.2; Glu213-Pro297). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography. |
| Source | Monoclonal Mouse IgG1 Clone #06 |
| Purification | Protein A |
| Formulation | 0.2 μm filtered solution in PBS |
| Conjugate | Unconjugated |
| Form | Liquid |
| Shipping | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
Synonyms: Anti-B1 Antibody; Anti-Bp35 Antibody; Anti-CD20 Antibody; Anti-CVID5 Antibody; Anti-FMC7 Antibody; Anti-LEU-16 Antibody; Anti-S7 Antibody
Image / Experimental Information
| Image 1 Description | Immunochemical staining CD20 in human tonsil with mouse monoclonal antibody at 1:60 dilution, formalin-fixed paraffin embedded sections. |
| Image 1 Alt Text | Human CD20 Immunohistochemistry(IHC) 20313 |
| Image 1 URL | Source image |
| Image 2 Description | Immunochemical staining CD20 in human tonsil with mouse monoclonal antibody at 1:60 dilution, formalin-fixed paraffin embedded sections. |
| Image 2 Alt Text | Human CD20 Immunohistochemistry(IHC) 20314 |
| Image 2 URL | Source image |
| Image 3 Description | Immunochemical staining CD20 in human tonsil with mouse monoclonal antibody at 1:60 dilution, formalin-fixed paraffin embedded sections. |
| Image 3 Alt Text | Human CD20 Immunohistochemistry(IHC) 21219 |
| Image 3 URL | Source image |
| Image 4 Description | Immunochemical staining CD20 in human tonsil with mouse monoclonal antibody at 1:60 dilution, formalin-fixed paraffin embedded sections. |
| Image 4 Alt Text | Human CD20 Immunohistochemistry(IHC) 21240 |
| Image 4 URL | Source image |
Background Information
| Full Name | membrane-spanning 4-domains, subfamily A, member 1 |
| Description | CD20 (membrane-spanning 4-domains, subfamily A, member 1), also known as MS4A1, is a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. CD20 / MS4A1 is expressed in all stages of B cell development except the first and last. CD20 / MS4A1 is present from pre-pre B cells through memory cells, but not on either pro-B cells or plasma cells. It is a B-lymphocyte surface molecule that plays a role in the development and differentiation of B-cells into plasma cells. CD20 / MS4A1may be involved in the regulation of B-cell activation and proliferation. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5(CVID5). CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections, and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B-cells are usually in the normal range but can be very low. |
| Research Areas |
|
| Tags |
|
| References |
|
title: Machine learning–based integrative analysis identifies CXCL13-driven tertiary lymphoid structures as favorable immune and prognostic features in osteosarcoma
authors: Jie Jiang; Jiuhui Xu; ...; Xiaodong Tang
journal: Cellular Oncology
date: 2026-05-16
pmid: 42143177
doi: 10.1007/s13402-026-01226-1
cited_by_count: 0
techniques: Immunofluorescence; Immunohistochemistry; Incubation; Microscopy; Multiplex Assay; Software
bioz_score: 94
